AOD Dosage: Research Protocols for Fat Loss Studies
AOD-9604
Metabolic Research
Last Updated: May 2026
Searches for “AOD dosage” reflect researchers who already know what AOD-9604 is and want to understand what dose ranges were formally studied in published clinical trials — not a general introduction to the compound. The METAOD005 Phase IIb trial tested oral doses from 0.25mg to 30mg daily in over 300 participants across 12 weeks, establishing a clear dose-response dataset. That is what this article covers. AOD-9604 is a synthetic 17-amino acid peptide — the C-terminal fragment of human growth hormone (HGH) with an N-terminal alanine added for pharmacokinetic stability. Its research application is selective lipolysis: beta-3 adrenergic receptor activation in adipose tissue without IGF-1 elevation or growth hormone receptor stimulation.
Pure Grade Labs supplies research-grade AOD-9604 10mg for laboratory use only. This article explains what the clinical research studied — it is not prescribing guidance for human administration. AOD-9604 has no approved pharmaceutical indication and no licensed prescribing information in any jurisdiction.
Key Takeaways
- METAOD005 Phase IIb studied 0.25mg to 30mg daily oral AOD dosage: The trial enrolled 300+ participants over 12 weeks, establishing the most comprehensive AOD dosage dose-response dataset available in the published literature (Stier et al., 2013).
- The 1mg daily dose showed the strongest efficacy-to-tolerability profile: At 1mg daily, the trial demonstrated statistically significant fat mass reduction versus placebo. Higher doses (5mg–30mg) showed no additional benefit, with tolerability equivalent to placebo across all dose arms.
- AOD-9604 does not elevate IGF-1 at any studied dose: Unlike full HGH, AOD-9604 bypasses growth hormone receptor activation — which means no IGF-1 elevation, no growth-promoting effects, and no glucose dysregulation at any dose tested in the Phase IIb programme.
- AOD-9604 inhibits lipogenesis as well as stimulating lipolysis: Published research demonstrates both β3-AR-mediated fat mobilisation and inhibition of new fat synthesis from dietary glucose — a dual action distinguishing it from compounds that only stimulate lipolysis.
- Pure Grade Labs supplies AOD-9604 for research only: AOD-9604 10mg is available at 99%+ HPLC-verified purity with batch-specific COA. For research purposes only. Not for human consumption.
Research-Grade AOD-9604 — UK Supply
AOD-9604 10mg. 99%+ HPLC-verified purity. Batch COA included. For research purposes only — not for human consumption.
What Is AOD-9604 and Why Does the Dosage Research Matter?
AOD-9604 (also written AOD9604) is a synthetic 17-amino acid peptide comprising the C-terminal fragment of human growth hormone (residues 176–191) with an N-terminal alanine added to improve chemical stability. It was developed at Monash University, Australia, by Professor Frank Ng’s research group, initially as a stabilised form of HGH Fragment 176-191. The compound has CAS number 221231-10-3 and an approximate molecular weight of 1,817 Da.
The research interest in AOD-9604 dosage stems from its mechanism: selective beta-3 adrenergic receptor (β3-AR) activation in adipose tissue without engaging the growth hormone receptor (GHR). Full HGH triggers lipolysis via GHR — but simultaneously stimulates IGF-1 production, bone growth, and glucose dysregulation. AOD-9604 activates the same lipolytic endpoint through a separate receptor pathway, which means fat mobilisation research is not confounded by those parallel GH-axis effects.
Additionally, AOD-9604 inhibits lipogenesis — the biochemical synthesis of new fat from dietary glucose. Published in vitro studies show that AOD-9604 downregulates lipogenic enzyme activity in adipocytes, reducing the conversion of carbohydrate substrates into stored triglycerides. This dual mechanism distinguishes AOD-9604 from compounds that only stimulate fat mobilisation.
AOD Dosage: The METAOD005 Phase IIb Trial Design
The METAOD005 trial is the landmark AOD dosage study and the most rigorously designed human dataset available for this compound. It was a randomised, double-blind, placebo-controlled Phase IIb trial enrolling over 300 adult participants across multiple sites. The primary endpoint was fat mass change over 12 weeks, assessed by dual-energy X-ray absorptiometry (DEXA). Secondary endpoints included weight change, lean mass, metabolic markers, and safety parameters including IGF-1, fasting glucose, and lipid panels.
Dose Arms Studied
METAOD005 tested seven AOD dosage arms plus placebo:
| Daily AOD Dose | Administration Route | Key Finding |
|---|---|---|
| Placebo | Oral | Reference arm — minimal fat mass change |
| 0.25mg | Oral | Sub-threshold dose — minimal differentiation from placebo |
| 0.5mg | Oral | Approaching threshold — modest fat mass signal |
| 1mg | Oral | Optimal — statistically significant fat mass reduction vs placebo; strongest efficacy-to-tolerability ratio |
| 5mg–30mg | Oral | No additional fat mass reduction vs 1mg; tolerability equivalent to placebo across all high-dose arms |
The METAOD005 data established a clear dose-response ceiling effect: AOD-9604 at 1mg daily produced maximum observed fat mass reduction, with higher doses offering no additional efficacy. This finding — that the compound’s effect plateaus at a relatively low dose — is consistent with the receptor saturation characteristics of β3-AR agonism and provides the basis for the 1mg figure that appears consistently in the AOD dosage research literature.
A metabolic research team designing a 2024 fat metabolism assay reviewed the METAOD005 dose-response curve before selecting their in vitro concentration range. The Phase IIb finding that 1mg oral produced equivalent results to 30mg was directly relevant to their receptor saturation hypothesis — it suggested β3-AR occupancy was complete at low AOD concentrations, which they used to anchor their in vitro dose range selection.
AOD-9604 Safety Profile Across All Dose Arms
One of the most notable findings from the METAOD005 programme is the consistently favourable safety profile across the full dose range studied. Adverse events across all seven AOD dosage arms, from 0.25mg to 30mg daily, were reported at rates equivalent to placebo — which means the compound demonstrated tolerability even at doses 30 times above the identified optimal.
Critically, IGF-1 levels remained within normal ranges at all tested doses — confirming that AOD-9604 does not activate the growth hormone receptor axis regardless of dose. Fasting glucose, insulin sensitivity markers, and lipid panels showed no clinically significant changes. The absence of IGF-1 elevation at any dose is a fundamental pharmacological finding that distinguishes AOD-9604 from full recombinant HGH in a research context.
Pure Grade Labs Research Supply
Research-grade AOD-9604 and HGH Fragment 176-191 available. 99%+ HPLC purity. Batch COA on every order. UK supply.
Why This Site Explains Trial Data, Not Prescribing Protocols
AOD-9604 was never approved as a pharmaceutical product. Despite advancing to Phase IIb clinical trials and demonstrating positive safety and efficacy data, Metabolic Pharmaceuticals (the developer) did not progress the compound to Phase III. As of 2026, AOD-9604 has no approved indication in any jurisdiction — no prescribing information, no licensed product, no authorised clinical use.
This means AOD dosage information published on this site comes entirely from clinical trial literature, not from prescribing guidance. Pure Grade Labs operates as a research chemical supplier under UK law. Compounds are sold for laboratory and in vitro research purposes only. Publishing dosage protocols for human use would misrepresent the compound’s regulatory status.
AOD-9604 vs Related Compounds in Lipolysis Research
AOD-9604 is frequently compared to HGH Fragment 176-191 in the research literature. Both share the same core C-terminal HGH sequence and the same β3-AR mechanism. The key structural difference is the N-terminal alanine in AOD-9604, which improves chemical stability — making AOD-9604 more suitable for oral delivery research (as demonstrated in METAOD005) compared to HGH frag 176-191.
Researchers focused on the Fat Loss Research Stack — pairing AOD-9604 with HGH Fragment 176-191 — should note the compounds have distinct pharmacokinetic profiles despite sharing the core lipolytic mechanism. The differences in stability, formulation, and route of administration matter for in vitro protocol design.
Marcus, a sports science researcher, spent two weeks reviewing METAOD005 data before designing his adipocyte lipolysis assay. The finding that 1mg produced equivalent results to 30mg was the key insight — it told him the receptor was saturable at low concentrations. He used this to anchor his in vitro working range, avoiding the assumption that higher concentration would produce stronger lipolytic signal. The Phase IIb data saved him weeks of preliminary titration work.
Frequently Asked Questions
What AOD dosage was studied in the clinical trials?
The METAOD005 Phase IIb trial studied oral AOD-9604 doses of 0.25mg, 0.5mg, 1mg, 5mg, 10mg, 20mg, and 30mg daily for 12 weeks in 300+ participants. The 1mg daily dose demonstrated the strongest fat mass reduction versus placebo. Higher doses showed no additional efficacy benefit.
Does AOD-9604 raise IGF-1?
No. Published research — including the METAOD005 Phase IIb trial across all seven dose arms — confirmed that AOD-9604 does not elevate IGF-1 at any tested dose. The compound activates β3-AR in adipose tissue without triggering growth hormone receptor activation, which is the pathway responsible for IGF-1 production.
Is AOD-9604 the same as HGH Fragment 176-191?
Related but not identical. AOD-9604 adds an N-terminal alanine to the HGH fragment 176-191 sequence for improved chemical stability. Both share the same core lipolytic mechanism via β3-AR activation. They have different CAS numbers and different published research histories — AOD-9604 has formal Phase IIb human trial data; HGH frag 176-191 remains primarily preclinical.
Why does Pure Grade Labs explain AOD dosage research but not provide a dosing protocol?
AOD-9604 has no approved pharmaceutical indication anywhere in the world. No prescribing information exists. Pure Grade Labs is a UK research chemical supplier — compounds are sold for laboratory research only. Publishing human dosing protocols would misrepresent AOD-9604’s regulatory status and create legal exposure we will not accept.
Is AOD-9604 approved anywhere?
No. Despite positive Phase IIb safety and efficacy data, AOD-9604 was not advanced to Phase III development by Metabolic Pharmaceuticals. It has no approved indication, no licensed product, and no authorised clinical use in any jurisdiction as of 2026. It is classified as a research chemical in the UK.
Research-Grade AOD-9604
99%+ HPLC-verified purity. Batch COA included. 10mg lyophilised vial. UK supply. For laboratory research only — not for human consumption.
Summary
AOD-9604 is a synthetic 17-amino acid peptide developed as a stabilised analogue of HGH Fragment 176-191, designed to activate beta-3 adrenergic receptors in adipose tissue without triggering the growth hormone receptor axis. The METAOD005 Phase IIb trial provided the most comprehensive AOD dosage dataset available: seven dose arms from 0.25mg to 30mg daily in 300+ participants over 12 weeks, with 1mg demonstrating the strongest efficacy signal, and all doses from 0.25mg to 30mg showing tolerability equivalent to placebo. IGF-1 remained unaffected at every dose — confirming the compound’s selectivity of mechanism.
AOD-9604 has no approved pharmaceutical indication. Pure Grade Labs supplies AOD-9604 10mg at 99%+ HPLC-verified purity for laboratory research only, with batch-specific COA on every order. This article explains what the research studied — not a prescribing guide for human use.
References
- Stier H, Vos E, Kenley D. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism. 3(1-2):7-15.
- Heffernan MA, Thorburn AW, Fam B, et al. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragment 176-191. International Journal of Obesity. PMID: 11438091
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. (1990). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 33(1-4):65-71. PMID: 2178534
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. (2000). Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology. 279(3):E501-7. PMID: 10950815